The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

The Effect of Taeksa-tang for Dyslipidemia: A Systematic Review and Meta-Analysis

이상지질혈증에 대한 택사탕(澤瀉湯)의 효과 : 체계적 문헌 고찰 및 메타 분석

  • Yeong-seo Lee (Dept. of Korean Internal Medicine, Dong-Eui University) ;
  • Tae-young Huh (Dept. of Korean Internal Medicine, Dong-Eui University) ;
  • Kyoung-min Kim (Dept. of Korean Internal Medicine, Dong-Eui University)
  • 이영서 (동의대학교 부속 한방병원 한방내과) ;
  • 허태영 (동의대학교 부속 한방병원 한방내과) ;
  • 김경민 (동의대학교 부속 한방병원 한방내과)
  • Received : 2023.05.30
  • Accepted : 2023.06.23
  • Published : 2023.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The purpose of this study is to assess the effectiveness and safety of using Taeksa-tang for dyslipidemia through a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: The search was conducted using keywords such as "dyslipidemia", "hyperlipidemia", "taeksa tang", "zexie tang", and "takusha to" in 12 databases (Pubmed, Cochrane, Embase, ScienceDirect, CNKI, Wanfang, CiNii, RISS, KISS, ScienceON, OASIS, and DBpia) on April 13, 2023. There were no limits on the publication period and language. Cochrane's risk of bias (RoB) was used to evaluate the quality of the studies. A meta-analysis was conducted according to the outcome measurements such as total effective rate (TER), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and adverse effects, using the Review Manager web. Results: A total of 9 RCTs were selected. In evaluating the RoB, 2 studies mentioning the random sequence generation, 1 study conducting double blindness, and 8 studies without missing values were evaluated as low risk, while 1 study without mentioning the random sequence generation was evaluated as high risk. All other parts were evaluated as unclear risk. The treatment group (Taeksa-tang or Taeksa-tang-gagam) showed more statistically significant effects compared to the control group (Western medicine or Chinese patent medicine) in TER (RR : 1.24, 95% CI 1.15 to 1.34, P<0.00001), TC (MD : -1.12, 95% CI -1.68 to -0.56, P<0.0001), TG (MD : -1.08, 95% CI -1.65 to -0.51, P=0.0002), HDL-C (MD : 0.63, 95% CI 0.34 to 0.93, P<0.0001), LDL-C (MD : -0.81, 95% CI -1.10 to -0.53, P<0.00001). In addition, the treatment group showed lower adverse effects compared to the control group (RR : 0.30, 95% CI 0.12 to 0.74, P=0.008). Conclusion: This study suggests that Taeksa-tang is effective and safe to use for treating dyslipidemia. However, due to the low quality of the included studies, more clinical studies need to be conducted in the future to increase the possibility of clinical use.

Keywords

References

  1. Cardiovascular diseases(CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) 
  2. Noh JW, Jeong SM, Kim DH, Yoo JH, Ahn YM, Ahn SY, et al. A Retrospective Study on the Effect of Daeshiho-tang on the Lipid Profile in Patients with Uncontrolled Dyslipidemia by Statins. J Int Korean Med 2019;40(6):1026-34.  https://doi.org/10.22246/jikm.2019.40.6.1026
  3. The Korean Society of Lipid and Atherosclerosis (KSoLA) Committee of Clinical Practice Guideline. Korean Guidelines for the Management of Dyslipidemia(the 5th edition). Seoul: The Korean Society of Lipid and Atherosclerosis; 2022, p. 19, 31-3, 45, 84, 94-125. 
  4. Ryu JY, Cho HK, Yoo HR, Seol IC, Kim YS. The Effects of Artemisiae Iwayomogii Herba, Curcumae Radix, and Aurantii Fructus Immaturus Complex Extract (ACA) on Dyslipidemia-related Factor Expression and Anti-oxidation in HepG2 Cells. J Int Korean Med 2017;38(3):367-75.  https://doi.org/10.22246/jikm.2017.38.3.367
  5. Kim KS, Cha MH, Lee SW, Yoon YS. A Study on the Inhibitory Effects of Scutellariae Radix on Fat Accumulation. Korean Journal of Oriental Medicine 2003;9(2):45-54. 
  6. An GY, Jo JJ, Shin MG, Jeon SY. Study of the effects of gugijagami-bang in a hyperlipidemic animal model induced with a high-fat diet. J Int Korean Med 2014;35(4):505-18. 
  7. Bang HJ, Tak ES, Hong Y, Kang YH. A Study on The Oriental-medical Understanding of Hyperlipidemia. The Journal of east-west medicines 1995;20(1):25-36. 
  8. 張仲景. 金匱要略心典 譯解. Seoul: Jipmoondang; 2008, p. 214-6. 
  9. Lee KJ, Ji NK, Cho KH. A case of dizziness patient suggested Benign Positional Vertigo treated by Zexictang. J Int Korean Med 1999;20(2):705-10. 
  10. Na HY, Lee SW, Yoo JH, Ahn SY, Lee BC, Ahn YM. A Case Report of Vertigo Patient with Vestibulopathy Improved with Zexie-tang. J Int Korean Med 2015;fal:123-8. 
  11. Lee YJ, Lee EB, Kim HJ, Yang DH, Kim YJ, An HD. The Effects of Taeksa-tang on Blood Lipid Profile and Anti Oxidation. J Korean Med Rehabil 2021;31(2):1-14.  https://doi.org/10.18325/jkmr.2021.31.2.1
  12. Nam SK, Lee DS, Kim NJ, Lee KS, Hong ND. Studies on the Efficacy of Combined Preparation of Crude Drugs(XXXI) - The Effect of Taeksa -tang on Diuresis, Serum Lipid, Isolated Ileum, Heart, Blood Vessel, Blood Pressure and Respiration. Korean Journal of Pharmacognosy 1986;17(4):263-71. 
  13. Hong YK, Kim SS, Shin MK, Kim JJ. Review of Korean Medical Treatment in Hyperlipidemia - Focusing on Treatment of Korean Herbal Medicine. Korean J Oriental Physiology & Pathology 2010;24(1):9-14. 
  14. Kim SY, Park JE, Seo HJ, Lee YJ, Jang BH, Son HJ, et al. NECA's Guidance for Undertaking Systematic Reviews and Meta-analyses for Intervention. Seoul: National Evidence-based Health care Collaborating Agency; 2011, p. 1-287. 
  15. Lee JY. Meta-anallysis. J Korean Endocrinolog 2008;23(6):361-78.  https://doi.org/10.3803/jkes.2008.23.6.361
  16. 顾国龙, 刘峥. 泽泻汤治疗高血压病合并高脂血症. 湖北中医杂志 2003;25(4):9-10. 
  17. 展照双, 王加锋. 茯苓泽泻汤加味治疗高脂蛋白血 症49例. 北京中医 2004;23(1):24-6. 
  18. 崔德成, 崔丽平. 自拟泽泻柴胡汤治疗高脂血症的 临床观察. 北京中医 2004;23(3):152-3. 
  19. 赵坤元. "首乌泽泻汤" 治疗高脂血症60例临床观察. 江苏中医药 2006;27(5):32-3. 
  20. 秦泗关, 张有涛, 吴晓青, 郝立鹏, 阳其娟. 大黄茯苓泽泻汤治疗2型糖尿病合并高脂血症临床观察. CJCM 2012;4(18):80-1. 
  21. 高源. 泽泻汤在高脂血症治疗中的应用效果观察. 世界最新医学信息文摘 2016;16(61):239-41. 
  22. 何杰先. 泽泻汤治疗高脂血症的临床疗效观察. 双足与保健 2017;26(12):178-9. 
  23. 李爱珍. 泽泻汤治疗高脂血症的临床疗效. 临床合理用药杂志 2018;11(36):114-5. 
  24. 李白云. 大黃蟅虫丸合泽泻汤加减治疗高脂血症60例临床观察. 哈尔滨医药 2019;39(2):187-8.  https://doi.org/10.26549/yzlcyxzz.v2i5.2668
  25. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69(2):231-6.  https://doi.org/10.1093/ajcn/69.2.231
  26. Liang L, Shao W, Shu T, Zhang Y, Xu S, Guo L, et al. Xuezhikang improves the outcomes of cardiopulmonary resuscitation in rats by suppressing the inflammation response through TLR4/NF-κB pathway. Biomed Pharmacother 2019;114:108817. 
  27. Xu G, Lin M, Dai X, Hu J. Comparing the effectiveness of Chinese patent medicines containing red yeast rice on hyperlipidaemia: A network meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab 2022;5(1):e00314. 
  28. Hao SY, Wang L, Li H, Zhang D, Xu H. Simultaneous determination of lovastatin and lovastatin acid in fermentum Rubrum and Zhibituo tablets by QAMS. Chin J Exp Trad Med Formulae 2017;23:74-8. 
  29. Khorshidi M, Zarezadeh M, Moradi Moghaddam O, Emami MR, Kord-Varkaneh H, Mousavi SM, et al. Effect of evening primrose oil supplementation on lipid profile: A systematic review and meta-analysis of randomized clinical trials. Phytother Res 2020;34(10):2628-38.  https://doi.org/10.1002/ptr.6716
  30. Statistics Korea. 2021 Death statistics. Daejeon: Statistics Korea; 2021. p. 6. 
  31. Arafa A, Lee HH, Eshak ES, Shirai K, Liu K, Li J, et al. Modifiable Risk Factors for Cardiovascular Disease in Korea and Japan. Korean Circ J 2021;51(8):643-55.  https://doi.org/10.4070/kcj.2021.0121
  32. Korea Disease Control and Prevenion Agency. 2020 Chronic Disease Status and Issues - Chronic Disease Factbook. Cheongju: Korea Disease Control and Prevenion Agency; 2020, p. 17-74. 
  33. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Current Atherosclerosis Reports 2013;15(1):291. 
  34. Lee SR, Ock MY, Kim HA. Comparison of Adverse Events between High-intensity and Moderate- to Low-intensity Statin Group. Korean J Clin Pharm 2018;28(4):293-9.  https://doi.org/10.24304/kjcp.2018.28.4.293
  35. Yang YG. The translation of Hwangjenaegyung. 1st edition. Seoul: Iljoongsa; 1991, p. 296-7, 416. 
  36. Heo J. Donguibogam. Seoul: Namsandang; 1975, p. 128, 202. 
  37. College of Oriental Medicine Herbology Compilation Committee. Herbology. 2nd edition. Seoul: Yeongrimsa; 2010, p. 348-9, 579-80.